Navigation Links
Kaiser Permanente Data Provides Strong Evidence for Continued Value of Combined Pap and HPV Testing

Evaluation of 800,000 Pap and HPV cotests concludes that "concerns about excessive HPV test positives...are not borne out"

VENLO, The Netherlands, March 24 /PRNewswire/ -- Physicians from Kaiser Permanente and the National Cancer Institute report in the March issue of Obstetrics & Gynecology that results from an evaluation of more than 800,000 Pap and HPV tests conducted at Northern California Kaiser Permanente dispel the notion that excessive numbers of women would require increased surveillance and follow-up when HPV testing is implemented. Cervical cancer is a preventable cancer with a primary known cause -- the human papillomavirus (HPV). QIAGEN developed and markets the digene(R) HPV Test, a cervical cancer screening test that detects the high-risk types of HPV that cause cervical cancer and identify women most at risk for developing the disease.

In the study "Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting," Dr. Philip E. Castle of the National Cancer Institute, together with Dr. Walter Kinney of Kaiser Permanente and a team of other contributors, focused on the early results of combining HPV and Pap testing for routine cervical cancer screening. Kaiser exclusively used QIAGEN's Hybrid Capture(R) 2 High-Risk HPV DNA Test for its HPV detection in the study (also called the digene HPV Test) and conventional cytology for its Pap testing.

The physicians reported that 90.8 percent of the 580,000 women aged 30 and older had "double-negative" results, meaning their Paps were normal and they did not have high-risk types of HPV so were at low risk for developing cervical cancer. Overall, 6.27 percent of cotests were carcinogenic HPV positive, and 2.28 percent showed carcinogenic HPV infection together with Pap results showing pre-cancerous cell changes or inconclusive results. Only 3.99 percent were found HPV-positive with a normal Pap result. Under Kaiser's previously published protocol, this group of women would be scheduled for re-testing in 12 months to monitor the persistence of HPV infection. The study authors concluded, "In a general screening population, concerns about excessive HPV test positives among women aged 30 years and older are not borne out."

Investigators also revealed that among those women who tested positive for high-risk HPV infection with the digene HPV Test, patients in the age segments of 30-34 years (10.82 percent) and 35-39 years (8.03 percent) had the highest infection rates and also were the groups with the highest prevalence of CIN2/3, thus reinforcing the clinical benefit of reserving routine HPV testing for women age 30 and higher.

"These study results illustrate the benefits to large health systems of combined screening with the digene HPV Test and a Pap for all women age 30 and older, and dispels the notion that excessive numbers of women would require increased surveillance and follow-up when HPV testing is implemented," said Dr. Jim Godsey, Senior Vice President Research & Development North America for QIAGEN. "Some doctors have exercised caution using HPV testing out of now-disproven concern that they would have a lot of patients with Pap normal/HPV positive test results who would require counseling and follow-up. This study clearly demonstrates that this is not the case, and importantly shows cotest outcome rates within the very large and diverse patient population that Kaiser serves. This is good news to the clinical community who may have been overly anxious about the management of a large number of HPV positive, Pap normal test results. In fact, by identifying the women who test positive for infection with one of the cancer causing types of HPV -- and who are hence at greater risk of developing cervical disease -- clinicians can more effectively direct treatment and follow-up, potentially detecting more early stage disease and saving lives."

Kaiser Permanente Northern California performs HPV testing with the digene HPV Test and provides Pap and HPV cotesting to its female patients age 30 and older to better identify those at risk of developing cervical cancer. The digene HPV Test detects the presence of high-risk types of HPV, the primary cause of cervical cancer. The test is recommended for use along with the Pap to screen women age 30 and older, the group most at risk of developing cervical cancer, as well as for follow-up evaluation in women whose Pap results are inconclusive.

"We recognize that women who test positive for carcinogenic HPV and negative by cytology are at an elevated risk for cervical pre-cancer and cancer compared with women who test negative on both," the study authors write, suggesting that future clinical research will need to focus on identifying "the best strategies for managing women who test positive for carcinogenic HPV and negative by cytology."

While the Pap test relies on a laboratory technician to manually look for cell changes that may signal cervical disease, QIAGEN's digene HPV Test, which uses the company's proprietary Hybrid Capture 2 (hc2) technology, uses advanced molecular technology to identify the presence of the genetic code (DNA) of 13 high-risk, cancer causing types of HPV. More than 40 million tests for carcinogenic HPV have been performed with the digene HPV Test. FDA-approved since 1999, the digene HPV Test has been published in more than 300 peer-reviewed journal articles and studied in clinical trials involving more than 825,000 women worldwide. It is quickly becoming a new standard-of-care for cervical cancer screening and is recognized as the "gold-standard" in HPV testing.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the leading FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kaiser Permanente Pasadena Marathon is Ready and Set to Go Sunday
2. Kaiser Permanente Ranked No. 7 on DiversityIncs Top 50 Companies for Diversity(R)
3. Pasadena Marathon Presented By Kaiser Permanente Hails Partnership With Tiffany & Co.
4. Kaiser Permanente Identifies Key Elements in Successful Health Care Information Technology Implementation
5. Kaiser Permanente Recognized as Best Place for Diverse Managers
6. Kidney Disease Increases the Risk of Stroke in Patients With the Most Common Type of Heart Arrhythmia, According to Kaiser Permanente Study
7. Kaiser Permanente Study Finds Drinking Wine May Lower Risk of Barretts Esophagus, Precursor to Nations Fastest Growing Cancer, Esophageal Cancer
8. Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results
9. Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008
10. Kaiser Permanente Provides Seed Funding to the Institute for Healthcare Improvements New Open School for Health Professions
11. Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Rehabilitation P.C.went to NASDAQ to educate the personnel on spinal decompression therapy and ... the spine, a nonsurgical procedure. The benefits come from creating negative intradiscal pressure ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... detailing the important role that meat and poultry play in a healthy, ... poultry, a nutrition quiz where visitors can check their “meat IQ,” a section ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:12/1/2015)... ... 01, 2015 , ... Henderson, a town of about 6,300 ... through a partnership this year with Aeneas Internet and Telephone. , With faster ... for entrepreneurs who want to build a business. Whether startups or long established ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and VANCOUVER , Dec. 1, 2015 ... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... on the pre-planned interim futility analysis of the intent-to-treat ... safety issues were identified by the DMC. Both the ... final results are expected in the second half of ...
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... 2015 ... "Medium Molecular Weight Polyisobutylene Market for ... Applications - Global Industry Analysis, Size, Share, ... report to their offering. --> ... of the "Medium Molecular Weight Polyisobutylene ...
Breaking Medicine Technology: